Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis

Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges lik...

Full description

Saved in:
Bibliographic Details
Published inBMC public health Vol. 24; no. 1; p. 220
Main Authors Du, Hongru, Saiyed, Samee, Gardner, Lauren M
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 18.01.2024
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems.
AbstractList Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. Methods In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Results Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. Conclusions This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. Keywords: COVID-19, Vaccination rates, Population-level, United States, Statistical analysis
Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. Methods In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Results Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. Conclusions This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems.
BackgroundPopulation-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes.MethodsIn this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves.ResultsOur study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves.ConclusionsThis study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems.
Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems.
In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems.
Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. Methods In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Results Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. Conclusions This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems.
ArticleNumber 220
Audience Academic
Author Du, Hongru
Saiyed, Samee
Gardner, Lauren M
Author_xml – sequence: 1
  givenname: Hongru
  surname: Du
  fullname: Du, Hongru
  email: hdu9@jhu.edu, hdu9@jhu.edu
  organization: Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA. hdu9@jhu.edu
– sequence: 2
  givenname: Samee
  surname: Saiyed
  fullname: Saiyed, Samee
  organization: Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA
– sequence: 3
  givenname: Lauren M
  surname: Gardner
  fullname: Gardner, Lauren M
  organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38238709$$D View this record in MEDLINE/PubMed
BookMark eNptUk1v1DAQjVAR_YA_wAFZ4sIlxR9xbHNbbWlZqVIPUK6WY0-6XmXjJXa66o2fjrMpK0DIh7HevPdmRnrnxUkfeiiKtwRfEiLrj5FQKVWJaVUSIRQu9y-KM1IJUtKKy5M__qfFeYwbjImQnL4qTpmkTAqszoqfixiD9Sb50KMG0h6gR4_GWt_P2GASRGR6h5Z331dXJVFoDaZLaxTGZMM2N32P0hrQfe8TOPQ1TYpPyKBd2I3dwaXs4BE6FHPLx-St6bKj6Z6ij6-Ll63pIrx5rhfF_fXnb8sv5e3dzWq5uC0txzKVAnPBW1FZYh0xRAlLmaIZwq6qCAPH60Y03NUNa2njZKuYVLhiBiRvqtayi2I1-7pgNno3-K0ZnnQwXh-AMDxoM-TVOtCAa3DQVqIxtLKCKllzYklruDKcUZa9PsxeuyH8GCEmvfXRQteZHsIYNVVEcM4EF5n6_h_qJoxDvn1iUV5jUmfmkfVg8nzftyENxk6meiEkJSofP429_A8rPwdbb3M2Wp_xvwR0FtghxDhAe7ybYD1FSM8R0jlC-hAhvc-id88bj80W3FHyOzPsF3I9wjU
CitedBy_id crossref_primary_10_1016_j_ijid_2024_107163
Cites_doi 10.1016/S1473-3099(22)00320-6
10.1038/s41591-021-01230-y
10.1016/S1473-3099(20)30553-3
10.1056/NEJMc2200133
10.3390/vaccines10050726
10.2139/ssrn.3951778
10.1056/NEJMoa2110345
10.46234/ccdcw2021.255
10.1001/jamanetworkopen.2020.26881
10.1016/j.ebiom.2023.104482
10.1016/S1473-3099(22)00578-3
10.1016/S0140-6736(22)00462-7
10.1016/S0140-6736(21)00947-8
10.1056/NEJMoa2101544
10.1016/j.vaccine.2023.05.056
10.1001/jamanetworkopen.2022.0536
10.1056/NEJMoa2035389
10.1001/jamanetworkopen.2022.28900
10.1016/S0140-6736(23)00461-0
10.1002/jmv.27697
10.1016/S0140-6736(22)01656-7
10.1016/S1473-3099(20)30120-1
10.1056/NEJMoa2203965
10.1016/j.vaccine.2021.05.099
10.3390/ijerph17207560
10.1002/rmv.2146
10.1126/science.abb4218
10.1038/s41586-020-2923-3
10.1371/journal.pone.0253116
10.1371/journal.pmed.1003992
10.1016/j.rceng.2020.08.002
10.1056/NEJMoa2114228
10.1001/jamainternmed.2022.4299
10.1016/S1473-3099(22)00801-5
10.15585/mmwr.mm7034e2
10.1377/hlthaff.2017.1166
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7T2
7X7
7XB
88E
8C1
8FE
8FG
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
AN0
ATCPS
AZQEC
BENPR
BGLVJ
BHPHI
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
L6V
M0S
M1P
M7S
PATMY
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
7X8
DOA
DOI 10.1186/s12889-024-17790-w
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Health and Safety Science Abstracts (Full archive)
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Public Health Database
ProQuest SciTech Collection
ProQuest Technology Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Agriculture & Environmental Science Database
ProQuest Central Essentials
ProQuest Central
Technology Collection
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest Engineering Database
Environmental Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
Environmental Science Collection
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
Technology Collection
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest Engineering Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Agricultural & Environmental Science Collection
Health & Safety Science Abstracts
ProQuest Medical Library (Alumni)
Engineering Collection
Engineering Database
ProQuest Public Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
Coronavirus Research Database
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Environmental Science Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
MEDLINE

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1471-2458
EndPage 220
ExternalDocumentID oai_doaj_org_article_e06edef47ba24c7298651c1fa59a5323
A782195753
10_1186_s12889_024_17790_w
38238709
Genre Journal Article
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation_xml – fundername: NSF Award
  grantid: 2229996
– fundername: NSF RAPID Award
  grantid: 2108526
GroupedDBID ---
-A0
0R~
23N
2WC
2XV
3V.
44B
53G
5VS
6J9
6PF
7X7
7XC
88E
8C1
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAJSJ
AAWTL
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACRMQ
ADBBV
ADINQ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AN0
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BNQBC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
ECM
EIF
EMB
EMK
EMOBN
ESTFP
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
L6V
M1P
M48
M7S
M~E
NPM
O5R
O5S
OK1
P2P
PATMY
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
CITATION
ABMYL
ABVAZ
AFGXO
AFNRJ
7T2
7XB
8FK
AZQEC
C1K
COVID
DWQXO
GNUQQ
K9.
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c508t-70575f74c1cd1a197c239275f0d4413ed56b7b5d6b3f2bd8f9389043ae85b4fc3
IEDL.DBID DOA
ISSN 1471-2458
IngestDate Tue Oct 22 15:15:54 EDT 2024
Fri Oct 25 11:08:23 EDT 2024
Thu Oct 10 18:55:46 EDT 2024
Wed Mar 13 18:28:13 EDT 2024
Tue Mar 12 05:00:47 EDT 2024
Thu Sep 12 19:15:07 EDT 2024
Sat Nov 02 12:24:04 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
Statistical analysis
Population-level
United States
Vaccination rates
Language English
License 2024. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-70575f74c1cd1a197c239275f0d4413ed56b7b5d6b3f2bd8f9389043ae85b4fc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/e06edef47ba24c7298651c1fa59a5323
PMID 38238709
PQID 2925601655
PQPubID 44782
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_e06edef47ba24c7298651c1fa59a5323
proquest_miscellaneous_2917553757
proquest_journals_2925601655
gale_infotracmisc_A782195753
gale_infotracacademiconefile_A782195753
crossref_primary_10_1186_s12889_024_17790_w
pubmed_primary_38238709
PublicationCentury 2000
PublicationDate 2024-01-18
PublicationDateYYYYMMDD 2024-01-18
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-18
  day: 18
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC public health
PublicationTitleAlternate BMC Public Health
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References T Nyberg (17790_CR39) 2022; 399
17790_CR27
17790_CR26
17790_CR29
Y Goldberg (17790_CR33) 2021; 385
17790_CR28
S Chang (17790_CR43) 2021; 589
MW Tenforde (17790_CR34) 2021; 70
HN Altarawneh (17790_CR6) 2022; 387
17790_CR21
17790_CR20
N Bobrovitz (17790_CR37) 2023; 23
17790_CR23
MU Kraemer (17790_CR42) 2020; 368
JY Chun (17790_CR46) 2021
17790_CR22
S Carazo (17790_CR36) 2023; 23
F Blavin (17790_CR40) 2018; 37
HS Badr (17790_CR41) 2020; 20
FP Havers (17790_CR45) 2022; 182
JA Quesada (17790_CR31) 2021; 221
G Ogedegbe (17790_CR16) 2020; 3
T Hale (17790_CR47) 2021; 16
U Agrawal (17790_CR10) 2022; 400
17790_CR14
17790_CR13
17790_CR15
OT Ng (17790_CR9) 2022; 5
C Faes (17790_CR32) 2020; 17
MK Patel (17790_CR5) 2021; 39
S Khare (17790_CR30) 2021; 3
17790_CR19
EJ Haas (17790_CR7) 2021; 397
H Du (17790_CR24) 2023; 89
H Wienkes (17790_CR44) 2022; 5
OJ Watson (17790_CR11) 2022; 22
JH Kim (17790_CR4) 2021; 27
R Wang (17790_CR12) 2022; 10
E Dong (17790_CR18) 2020; 20
LR Baden (17790_CR1) 2021; 384
HN Altarawneh (17790_CR38) 2022; 386
T Hale (17790_CR25) 2020; 8
S Chenchula (17790_CR35) 2022; 94
J Sadoff (17790_CR2) 2021; 384
SJ Thomas (17790_CR3) 2021; 385
MA Gram (17790_CR8) 2022; 19
B Gallo Marin (17790_CR17) 2021; 31
References_xml – volume: 22
  start-page: 1293
  year: 2022
  ident: 17790_CR11
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(22)00320-6
  contributor:
    fullname: OJ Watson
– ident: 17790_CR22
– volume: 27
  start-page: 205
  year: 2021
  ident: 17790_CR4
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01230-y
  contributor:
    fullname: JH Kim
– volume: 20
  start-page: 1247
  year: 2020
  ident: 17790_CR41
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(20)30553-3
  contributor:
    fullname: HS Badr
– ident: 17790_CR26
– ident: 17790_CR28
– volume: 386
  start-page: 1288
  year: 2022
  ident: 17790_CR38
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2200133
  contributor:
    fullname: HN Altarawneh
– volume: 10
  start-page: 726
  year: 2022
  ident: 17790_CR12
  publication-title: Vaccines
  doi: 10.3390/vaccines10050726
  contributor:
    fullname: R Wang
– year: 2021
  ident: 17790_CR46
  publication-title: SSRN Electron J
  doi: 10.2139/ssrn.3951778
  contributor:
    fullname: JY Chun
– volume: 385
  start-page: 1761
  year: 2021
  ident: 17790_CR3
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2110345
  contributor:
    fullname: SJ Thomas
– volume: 3
  start-page: 1049
  year: 2021
  ident: 17790_CR30
  publication-title: China CDC Wkly
  doi: 10.46234/ccdcw2021.255
  contributor:
    fullname: S Khare
– volume: 3
  start-page: e2026881
  year: 2020
  ident: 17790_CR16
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2020.26881
  contributor:
    fullname: G Ogedegbe
– ident: 17790_CR20
– volume: 89
  start-page: 104482
  year: 2023
  ident: 17790_CR24
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2023.104482
  contributor:
    fullname: H Du
– volume: 23
  start-page: 45
  year: 2023
  ident: 17790_CR36
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(22)00578-3
  contributor:
    fullname: S Carazo
– volume: 399
  start-page: 1303
  year: 2022
  ident: 17790_CR39
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(22)00462-7
  contributor:
    fullname: T Nyberg
– ident: 17790_CR13
– volume: 397
  start-page: 1819
  year: 2021
  ident: 17790_CR7
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(21)00947-8
  contributor:
    fullname: EJ Haas
– volume: 384
  start-page: 2187
  year: 2021
  ident: 17790_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2101544
  contributor:
    fullname: J Sadoff
– ident: 17790_CR15
  doi: 10.1016/j.vaccine.2023.05.056
– volume: 5
  start-page: e220536
  year: 2022
  ident: 17790_CR44
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2022.0536
  contributor:
    fullname: H Wienkes
– volume: 384
  start-page: 403
  year: 2021
  ident: 17790_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2035389
  contributor:
    fullname: LR Baden
– volume: 5
  start-page: e2228900
  year: 2022
  ident: 17790_CR9
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2022.28900
  contributor:
    fullname: OT Ng
– ident: 17790_CR14
  doi: 10.1016/S0140-6736(23)00461-0
– ident: 17790_CR23
– volume: 94
  start-page: 2969
  year: 2022
  ident: 17790_CR35
  publication-title: J Med Virol
  doi: 10.1002/jmv.27697
  contributor:
    fullname: S Chenchula
– volume: 400
  start-page: 1305
  year: 2022
  ident: 17790_CR10
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(22)01656-7
  contributor:
    fullname: U Agrawal
– volume: 20
  start-page: 533
  year: 2020
  ident: 17790_CR18
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(20)30120-1
  contributor:
    fullname: E Dong
– ident: 17790_CR27
– ident: 17790_CR19
– ident: 17790_CR29
– volume: 387
  start-page: 21
  year: 2022
  ident: 17790_CR6
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2203965
  contributor:
    fullname: HN Altarawneh
– volume: 39
  start-page: 4013
  year: 2021
  ident: 17790_CR5
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.05.099
  contributor:
    fullname: MK Patel
– volume: 8
  start-page: 30
  year: 2020
  ident: 17790_CR25
  publication-title: Last Updat
  contributor:
    fullname: T Hale
– volume: 17
  start-page: 7560
  year: 2020
  ident: 17790_CR32
  publication-title: Int J Environ Res Public Health
  doi: 10.3390/ijerph17207560
  contributor:
    fullname: C Faes
– ident: 17790_CR21
– volume: 31
  start-page: 1
  year: 2021
  ident: 17790_CR17
  publication-title: Rev Med Virol
  doi: 10.1002/rmv.2146
  contributor:
    fullname: B Gallo Marin
– volume: 368
  start-page: 493
  year: 2020
  ident: 17790_CR42
  publication-title: Science
  doi: 10.1126/science.abb4218
  contributor:
    fullname: MU Kraemer
– volume: 589
  start-page: 82
  year: 2021
  ident: 17790_CR43
  publication-title: Nature
  doi: 10.1038/s41586-020-2923-3
  contributor:
    fullname: S Chang
– volume: 16
  start-page: e0253116
  year: 2021
  ident: 17790_CR47
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0253116
  contributor:
    fullname: T Hale
– volume: 19
  start-page: e1003992
  year: 2022
  ident: 17790_CR8
  publication-title: PLOS Med
  doi: 10.1371/journal.pmed.1003992
  contributor:
    fullname: MA Gram
– volume: 221
  start-page: 109
  year: 2021
  ident: 17790_CR31
  publication-title: Rev Clínica Esp Engl Ed
  doi: 10.1016/j.rceng.2020.08.002
  contributor:
    fullname: JA Quesada
– volume: 385
  start-page: e85
  year: 2021
  ident: 17790_CR33
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2114228
  contributor:
    fullname: Y Goldberg
– volume: 182
  start-page: 1071
  year: 2022
  ident: 17790_CR45
  publication-title: JAMA Intern Med
  doi: 10.1001/jamainternmed.2022.4299
  contributor:
    fullname: FP Havers
– volume: 23
  start-page: 556
  year: 2023
  ident: 17790_CR37
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(22)00801-5
  contributor:
    fullname: N Bobrovitz
– volume: 70
  start-page: 1156
  year: 2021
  ident: 17790_CR34
  publication-title: Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm7034e2
  contributor:
    fullname: MW Tenforde
– volume: 37
  start-page: 299
  year: 2018
  ident: 17790_CR40
  publication-title: Health Aff (Millwood)
  doi: 10.1377/hlthaff.2017.1166
  contributor:
    fullname: F Blavin
SSID ssj0017852
Score 2.4492009
Snippet Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts....
Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating...
Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease...
In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on...
BackgroundPopulation-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease...
BACKGROUNDPopulation-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease...
Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating...
SourceID doaj
proquest
gale
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage 220
SubjectTerms Analysis
Care and treatment
Clinical trials
Cohort analysis
Comorbidity
Confounding (Statistics)
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 vaccines
Critical components
Diagnosis
Disease control
Disease transmission
Expenditures
Fatalities
Government programs
Health care
Health policy
Herd immunity
Hospitalization
Humans
Infections
Medical care, Cost of
Mortality
mRNA vaccines
Outcome Assessment, Health Care
Pandemics
Population (statistical)
Population-level
Public health
Public policy
Regression analysis
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Social factors
Statistical analysis
Surveillance
Time dependence
United States
United States - epidemiology
Vaccination
Vaccination rates
Vaccine efficacy
Vaccines
Variables
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZge0FCiDcLBRkJiQOymtixHXNBbWlVkCgIUdSb5UdSVULJspulV346M7E3sCBxjWeTrGc8-WY885mQF6p2WBkkGFLDsErWnhkfWhZNbEUlisK3mND_cKpOzqr35_I8J9xWuaxy4xNHRx37gDnyPW7G4EFJ-WbxneGpUbi7mo_QuE52OEQKfEZ2Do5OP32e9hF0LfmmVaZWeyvwxlgixCtWItEeu9r6HI2s_f_65r8Q5_jlOb5NbmXISPeTju-Qa013l9xM-Taa2ojukZ9_zDPNxVf0hwvhMqX7KFJCrKjrIj38-PXdW1Yamnogab8eYApg8LKjAAdpgqE0wdDX1NHFdMgX-4Y1RhS7kEaCZ3gtl1lN7pOz46Mvhycsn67AAoCygWlEaq2uQhli6UqjAwesBJeKCBBJNFEqr72MyouW-1i3BrBNUQnX1NJXbRAPyKzru-YRoSa0jUZBA8GiLpQHnOEFhlYA78CHzMmrzSTbRSLRsGPwUSubVGJBJXZUib2akwPUwySJBNjjhX55YfN6sk2hmti0lfaOVwEihFrJMpStk8ZJweGRL1GLFpfpsHTB5W4DeGEkvLL7gIxKAzMAkrtbkrC8wvbwxg5sXt4r-9sY5-T5NIy_xJK1runXKAPITAot9Zw8TPYz_SXcfAVHaR7__-ZPyA2OtlqUrKx3yWxYrpungIEG_ywb-i9VfARc
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA-1vggifnu1SgTBB4luNl8bQaRWSxXUF0_6FpJsIoWyV-_2Wn3zT3dms3d62kdfN7NsNjOT_CaZ-YWQx7rxmBkkGFLDMKmawGyImbW2zUKKqgoZN_Q_fNSHU_n-SB1tkdV1R-MALi4M7fA-qen85Nn3bz9egcO_HBy-0c8XMMdi4k8tGUf6PHZ-iVyukZgLU_nk71MF06h6VThz4Xsbi9PA4f_vTP0X_hzWoYPr5NoIIOle0fgNspW6m-Rq2X2jpajoFvn5x6jTMRWLnvkYj8vmH0WCiAX1XUv3P31594ZxS0tFJJ0tezBCaDzuKIBDWkApLaD0BfX0dH3lFzvBjCOKNUkD3TN0y48cJ7fJ9ODt5_1DNt61wCJAtJ4ZxG3ZyMhjyz23JtaAnOBR1QJgEqlVOpigWh1ErkPbZAtIp5LCp0YFmaO4Q7a7WZfuEWpjTgYFLYSOptIBUEcQGGgB2IMZZUKergbZnRZKDTeEIo12RSUOVOIGlbjzCXmNelhLIh328GA2_-pG73Kp0qlNWZrgaxkhXmi04pFnr6xXooZPPkEtOjSjfu6jH2sPoMNIf-X2ACdxCyMAkrsbkuBscbN5ZQduZauutkNcq5WakEfrZnwTE9i6NFuiDOA0JYwyE3K32M_6l_AoFqZNu_M_fvU-uVKjRVec8WaXbPfzZXoAuKkPDwdn-AUBKxOQ
  priority: 102
  providerName: Scholars Portal
Title Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/38238709
https://www.proquest.com/docview/2925601655
https://search.proquest.com/docview/2917553757
https://doaj.org/article/e06edef47ba24c7298651c1fa59a5323
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA9aL4KI3x1blwiCBwmdTCZf3rpr1yq0SrGyeAlJJgMFmS3dXXvtn-57k9mlqwcvXjKQvIFM3kvye5n3fiHkjTIeI4MEQ2oYVksTmA2xZY1tWlGLsgwtHuifnKrj8_rzTM5uXfWFMWGZHjgP3EEqVWpSW-vgqzoCFDRK8shbL62Xoso8n6VdO1PD_wNtZLVOkTHqYAGrMIYGVTXjSLDHrre2oZ6t_-81-Q-k2e8400fk4QAV6WHu4mNyJ3VPyIN8zkZz-tBTcnNrfOkQdEV_-Rgv8jEfRSqIBfVdQydfvn_6wLilOfeRzldLMDdovOgowECa4SfN8PM99fRyc7kX-4mxRRSzj3piZ-iWH9hMnpHz6dG3yTEbblVgEcDYkmlEaK2uI48N99zqWAFGgqqyAWgkUiNV0EE2Koi2Co1pLWCashY-GRnqNornZKebd2mXUBvbpFHQgpOoSxUAXwSBLhXAOlg7CvJuPcjuMpNnuN7pMMpllThQietV4q4LMkY9bCSR-LqvAHNwgzm4f5lDQd6iFh1Oz-WVj37IMoAOI9GVOwRExC2MAEjub0nCtIrbzWs7cMO0XrjK9h6skrIgrzfN-CaGqnVpvkIZQGRSaKkL8iLbz-aT8KcrLJD25f_41D1yv0KLLjnjZp_sLK9W6RUgpGUYkbt6pqE0E47l9OOI3BsfnX49g2dvbKN-ukB5Uhsoz8Y_fgNXHBNT
link.rule.ids 315,783,787,867,2109,12070,12237,12779,21402,24332,27938,27939,31733,31734,33280,33281,33387,33388,33758,33759,38530,43324,43593,43614,43819,43909
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagPYCEeD8WChgJiQNym4cdx1xQKVRbaMulRb1ZthOjqlWy7GapxImfzkzsBLZIHLjGk8TJjMefxzOfCXlZlAYzg3KG1DCMi9IyZZ1nlap8zvMksR4D-geHxfSYfzwRJzHgtohplYNP7B111TqMkW9lql88FEK8nX1jeGoU7q7GIzSuknWYWBOw6vWdz1_23o_7CLIU2VAqUxZbC_DGmCKUcZYi0R67WJmOetb-v33zJcTZzzy7t4ge-hwSTs42l53ddD8u0Tn-_0fdJjcjKKXbwYrukCt1c5fcCBE9GgqV7pGff2iSxvQu-t04dxoCihRJJxbUNBXt_w5LFQ1VlrRddtAfaDxtKABOGoAuDUD3DTV0Nh4jxs4xi4linVNPIQ3dMpE35T453v1wtDNl8fwG5gD2dUwiFvSSu9RVqUmVdBmgMbiUVADC8roShZVWVIXNfWar0itATwnPTV0Ky73LH5C1pm3qR4Qq52uJgqBkLpPCApKxOS7eAECCl5qQ14Ma9SzQdOh-eVMWOihdg9J1r3R9MSHvUNOjJFJs9xfa-VcdR6yuk6Kuas-lNRl3sAYpC5G61BuhjMgzeOUrtBONjqCbG2diPQN0GCm19DZgr1TBHwDJjRVJGMButXkwDh0dyEL_towJeTE2452YFNfU7RJlAPuJXAo5IQ-DhY6fhNu74IrV438__Dm5Nj062Nf7e4efnpDrGY6MJGVpuUHWuvmyfgqIq7PP4rD6BSfXKjc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+vaccination+rates+and+COVID-19+health+outcomes+in+the+United+States%3A+a+population-level+statistical+analysis&rft.jtitle=BMC+public+health&rft.au=Hongru+Du&rft.au=Samee+Saiyed&rft.au=Lauren+M.+Gardner&rft.date=2024-01-18&rft.pub=BMC&rft.eissn=1471-2458&rft.volume=24&rft.issue=1&rft.spage=1&rft.epage=14&rft_id=info:doi/10.1186%2Fs12889-024-17790-w&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e06edef47ba24c7298651c1fa59a5323
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon